Replacement of glucose with N-acetylglucosamine in peritoneal dialysis fluid - Experimental study in rats

Andrzej Breborowicz, Malgorzata Pawlaczyk-Kuzlan, Krysztof Pawlaczyk, Ewa Baum, Paul Tam, George Wu

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

◆ Background: Glucose is still used as an osmotic solute in peritoneal dialysis fluids, despite evidence of its local (peritoneal) and systemic toxicities. However a constant search is underway for a new, more biocompatible osmotic solute for peritoneal dialysis fluids. ◆ Objective: The present study evaluated N-acetylglucosamine (NAG) in a concentration of 220 mmol/L as an alternative to glucose for the osmotic solute in peritoneal dialysis fluid, during chronic peritoneal dialysis in rats. ◆ Methods: For 8 weeks, male Wistar rats were infused with glucose-based or NAG-based dialysis fluid. Intraperitoneal inflammation and peritoneal permeability and morphology were evaluated in all rats during the study. ◆ Results: Repeated intraperitoneal infusion of the NAG-based dialysis fluid resulted in a weaker intra-abdominal inflammatory reaction as compared with the reaction in rats infused with glucose-based dialysis solution. At the end of the study, the concentration of hyaluronan in the peritoneal interstitium obtained from NAG-treated rats was higher than that found in the interstitium taken from animals exposed to dialysis fluid containing glucose. Also, peritoneal permeability to total protein was lower in NAG-treated rats. ◆ Conclusion: As an alternative to glucose, NAG used for the osmotic solute in peritoneal dialysis solution decreases the intraperitoneal inflammatory reaction induced by the process of peritoneal dialysis and, indirectly (owing to the increased hyaluronan content in the peritoneal interstitium), diminishes peritoneal permeability to protein.

Original languageEnglish (US)
JournalPeritoneal Dialysis International
Volume21
Issue numberSUPPL. 3
StatePublished - 2001
Externally publishedYes

Fingerprint

Acetylglucosamine
Ascitic Fluid
Peritoneal Dialysis
Glucose
Dialysis
Permeability
Dialysis Solutions
Hyaluronic Acid
Parenteral Infusions
Wistar Rats
Proteins
Inflammation

Keywords

  • Inflammation
  • N-acetylglucosamine

ASJC Scopus subject areas

  • Nephrology

Cite this

Breborowicz, A., Pawlaczyk-Kuzlan, M., Pawlaczyk, K., Baum, E., Tam, P., & Wu, G. (2001). Replacement of glucose with N-acetylglucosamine in peritoneal dialysis fluid - Experimental study in rats. Peritoneal Dialysis International, 21(SUPPL. 3).

Replacement of glucose with N-acetylglucosamine in peritoneal dialysis fluid - Experimental study in rats. / Breborowicz, Andrzej; Pawlaczyk-Kuzlan, Malgorzata; Pawlaczyk, Krysztof; Baum, Ewa; Tam, Paul; Wu, George.

In: Peritoneal Dialysis International, Vol. 21, No. SUPPL. 3, 2001.

Research output: Contribution to journalArticle

Breborowicz, A, Pawlaczyk-Kuzlan, M, Pawlaczyk, K, Baum, E, Tam, P & Wu, G 2001, 'Replacement of glucose with N-acetylglucosamine in peritoneal dialysis fluid - Experimental study in rats', Peritoneal Dialysis International, vol. 21, no. SUPPL. 3.
Breborowicz, Andrzej ; Pawlaczyk-Kuzlan, Malgorzata ; Pawlaczyk, Krysztof ; Baum, Ewa ; Tam, Paul ; Wu, George. / Replacement of glucose with N-acetylglucosamine in peritoneal dialysis fluid - Experimental study in rats. In: Peritoneal Dialysis International. 2001 ; Vol. 21, No. SUPPL. 3.
@article{54b0d5db9f4047f082559251baa88c8b,
title = "Replacement of glucose with N-acetylglucosamine in peritoneal dialysis fluid - Experimental study in rats",
abstract = "◆ Background: Glucose is still used as an osmotic solute in peritoneal dialysis fluids, despite evidence of its local (peritoneal) and systemic toxicities. However a constant search is underway for a new, more biocompatible osmotic solute for peritoneal dialysis fluids. ◆ Objective: The present study evaluated N-acetylglucosamine (NAG) in a concentration of 220 mmol/L as an alternative to glucose for the osmotic solute in peritoneal dialysis fluid, during chronic peritoneal dialysis in rats. ◆ Methods: For 8 weeks, male Wistar rats were infused with glucose-based or NAG-based dialysis fluid. Intraperitoneal inflammation and peritoneal permeability and morphology were evaluated in all rats during the study. ◆ Results: Repeated intraperitoneal infusion of the NAG-based dialysis fluid resulted in a weaker intra-abdominal inflammatory reaction as compared with the reaction in rats infused with glucose-based dialysis solution. At the end of the study, the concentration of hyaluronan in the peritoneal interstitium obtained from NAG-treated rats was higher than that found in the interstitium taken from animals exposed to dialysis fluid containing glucose. Also, peritoneal permeability to total protein was lower in NAG-treated rats. ◆ Conclusion: As an alternative to glucose, NAG used for the osmotic solute in peritoneal dialysis solution decreases the intraperitoneal inflammatory reaction induced by the process of peritoneal dialysis and, indirectly (owing to the increased hyaluronan content in the peritoneal interstitium), diminishes peritoneal permeability to protein.",
keywords = "Inflammation, N-acetylglucosamine",
author = "Andrzej Breborowicz and Malgorzata Pawlaczyk-Kuzlan and Krysztof Pawlaczyk and Ewa Baum and Paul Tam and George Wu",
year = "2001",
language = "English (US)",
volume = "21",
journal = "Peritoneal Dialysis International",
issn = "0896-8608",
publisher = "Multimed Inc.",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Replacement of glucose with N-acetylglucosamine in peritoneal dialysis fluid - Experimental study in rats

AU - Breborowicz, Andrzej

AU - Pawlaczyk-Kuzlan, Malgorzata

AU - Pawlaczyk, Krysztof

AU - Baum, Ewa

AU - Tam, Paul

AU - Wu, George

PY - 2001

Y1 - 2001

N2 - ◆ Background: Glucose is still used as an osmotic solute in peritoneal dialysis fluids, despite evidence of its local (peritoneal) and systemic toxicities. However a constant search is underway for a new, more biocompatible osmotic solute for peritoneal dialysis fluids. ◆ Objective: The present study evaluated N-acetylglucosamine (NAG) in a concentration of 220 mmol/L as an alternative to glucose for the osmotic solute in peritoneal dialysis fluid, during chronic peritoneal dialysis in rats. ◆ Methods: For 8 weeks, male Wistar rats were infused with glucose-based or NAG-based dialysis fluid. Intraperitoneal inflammation and peritoneal permeability and morphology were evaluated in all rats during the study. ◆ Results: Repeated intraperitoneal infusion of the NAG-based dialysis fluid resulted in a weaker intra-abdominal inflammatory reaction as compared with the reaction in rats infused with glucose-based dialysis solution. At the end of the study, the concentration of hyaluronan in the peritoneal interstitium obtained from NAG-treated rats was higher than that found in the interstitium taken from animals exposed to dialysis fluid containing glucose. Also, peritoneal permeability to total protein was lower in NAG-treated rats. ◆ Conclusion: As an alternative to glucose, NAG used for the osmotic solute in peritoneal dialysis solution decreases the intraperitoneal inflammatory reaction induced by the process of peritoneal dialysis and, indirectly (owing to the increased hyaluronan content in the peritoneal interstitium), diminishes peritoneal permeability to protein.

AB - ◆ Background: Glucose is still used as an osmotic solute in peritoneal dialysis fluids, despite evidence of its local (peritoneal) and systemic toxicities. However a constant search is underway for a new, more biocompatible osmotic solute for peritoneal dialysis fluids. ◆ Objective: The present study evaluated N-acetylglucosamine (NAG) in a concentration of 220 mmol/L as an alternative to glucose for the osmotic solute in peritoneal dialysis fluid, during chronic peritoneal dialysis in rats. ◆ Methods: For 8 weeks, male Wistar rats were infused with glucose-based or NAG-based dialysis fluid. Intraperitoneal inflammation and peritoneal permeability and morphology were evaluated in all rats during the study. ◆ Results: Repeated intraperitoneal infusion of the NAG-based dialysis fluid resulted in a weaker intra-abdominal inflammatory reaction as compared with the reaction in rats infused with glucose-based dialysis solution. At the end of the study, the concentration of hyaluronan in the peritoneal interstitium obtained from NAG-treated rats was higher than that found in the interstitium taken from animals exposed to dialysis fluid containing glucose. Also, peritoneal permeability to total protein was lower in NAG-treated rats. ◆ Conclusion: As an alternative to glucose, NAG used for the osmotic solute in peritoneal dialysis solution decreases the intraperitoneal inflammatory reaction induced by the process of peritoneal dialysis and, indirectly (owing to the increased hyaluronan content in the peritoneal interstitium), diminishes peritoneal permeability to protein.

KW - Inflammation

KW - N-acetylglucosamine

UR - http://www.scopus.com/inward/record.url?scp=0035571598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035571598&partnerID=8YFLogxK

M3 - Article

C2 - 11887857

AN - SCOPUS:0035571598

VL - 21

JO - Peritoneal Dialysis International

JF - Peritoneal Dialysis International

SN - 0896-8608

IS - SUPPL. 3

ER -